Program
zongertinib
Also written as “Zongertinib”, “zongertinib (C-14)” and “Zongertinib, Formulation A, reference product”.
Its studies are mostly in Lung Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Liver Diseases · Carcinoma, Non-Small-Cell Lung, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 157 open or running | phase 3since Nov 22, 2023 | May 4, 2021 | Dec 10, 2026phase 3 · NCT06151574 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since May 4, 2021.
- Feb 28, 2023Phase 1 study in HealthyNCT05833139 · 16 enrolled · Germany
- May 25, 2023Phase 1 study in HealthyNCT05879991 · 15 enrolled · Netherlands
- Aug 30, 2023Phase 1 study in HealthyNCT06028464 · 16 enrolled · Germany
- Oct 4, 2023Phase 1 study in HealthyNCT06075277 · 16 enrolled · Germany
- Nov 22, 2023Phase 3 study in Lung NeoplasmsNCT06151574 · 428 enrolled · United States, Argentina, Australia and more
- Mar 15, 2024Phase 2 study in Breast NeoplasmsNCT06324357 · 910 planned · United States, Belgium, China and more
- Jul 3, 20242 phase 1 studies in HealthyNCT06494761, NCT06504862
- Aug 30, 2024Phase 2 study in Solid TumoursNCT06581432 · 588 planned · United States, Australia, Belgium and more
- Nov 15, 2024Phase 1 study in Liver DiseasesNCT06692322 · 29 enrolled · United States
- Sep 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07195695 · 400 planned · United States, Argentina, Australia and more
- Mar 12, 2026Phase 2 study in Lung NeoplasmsNCT07486817 · 60 planned · Australia, China, France and more
- Jun 11, 2026Phase 1 study in HealthyNCT07649941 · 16 enrolled · Germany
- Aug 24, 2026Phase 1 study in HealthyNCT07789028 · 56 planned · Germany
- Oct 28, 2026Primary completion moved from 2026-12-30 to 2028-02-29Date moved laterphase 1 · +14 months · NCT04886804
Ahead
- Dec 10, 2026Primary completion: phase 3 study in Lung NeoplasmsNCT06151574
- Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07789028
- Aug 12, 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07486817
- Feb 29, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT04886804
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07789028Healthy · Germany | 1 | Recruiting | Dec 15, 2026 | 56 |
| NCT07649941Healthy · Germany | 1 | Completed | Jul 31, 2026 | 16 |
| NCT07486817Lung Neoplasms · Australia, China, France and more | 2 | Recruiting | Aug 12, 2027 | 60 |
| NCT07195695Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Feb 26, 2032 | 400 |
| NCT06692322Liver Diseases · United States | 1 | Completed | Jun 20, 2025 | 29 |
| NCT06581432Solid Tumours · United States, Australia, Belgium and more | 2 | Recruiting | Nov 30, 2028 | 588 |
| NCT06504862Healthy · Germany | 1 | Completed | Oct 3, 2024 | 32 |
| NCT06494761Healthy · Germany | 1 | Completed | Oct 16, 2024 | 16 |
| NCT06324357Breast Neoplasms · United States, Belgium, China and more | 2 | Recruiting | Jan 8, 2029 | 910 |
| NCT06151574Lung Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 10, 2026 | 428 |
| NCT06075277Healthy · Germany | 1 | Completed | Jan 2, 2024 | 16 |
| NCT06028464Healthy · Germany | 1 | Completed | Dec 8, 2023 | 16 |
| NCT05879991Healthy · Netherlands | 1 | Completed | Oct 19, 2023 | 15 |
| NCT05833139Healthy · Germany | 1 | Completed | Jun 12, 2023 | 16 |
| NCT04886804Neoplasm Metastasis · United States, Australia, Austria and more | 1 | Recruiting | Feb 29, 2028 | 554 |
How it is read
Names in the registry
- “Zongertinib”, 9 entries
- “zongertinib”, 5 entries
- “zongertinib (C-14)”, 2 entries
- “Zongertinib, Formulation A, reference product”, 1 entry
- “Zongertinib Formulation B, test product”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 2 studies
- Breast Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Liver Diseases, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.